Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 28, 2011 Brian Orelli	One Step Closer to an FDA Decision Cell Therapeutics is still risky, though.
The Motley Fool December 31, 2011 Brian Orelli	3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012.
The Motley Fool September 17, 2010 Luke Timmerman	Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders?
The Motley Fool January 28, 2011 Brian Orelli	Value Investing, Biotech Style Biotech investors should regard every binary event as a varying degree of confidence in a positive or negative result.
The Motley Fool June 15, 2011 Brian Orelli	Investors Need a Peephole Into FDA Offices Cell Therapeutics is gung ho about its resubmission, but investors only get one side of the story.
The Motley Fool June 15, 2005 Brian Gorman	Cell Therapeutics' Gamble The biotech company's struggles are far from over. Without an approved drug on the market or the certainty of FDA clearance, the firm won't have an easy time finding investors.
The Motley Fool October 19, 2011 Dan Caplinger	Has Annaly Capital Become the Perfect Stock? With its leveraged model, Annaly will never be a perfect 10 on our scale. But it's close.
The Motley Fool November 16, 2009 Chris Jones	Make This Mine Yours (Now!) Taseko is still a screaming buy. In the investing world, with its impressive mineral reserves, Taseko Mines is among the most underappreciated companies in its industry.
The Motley Fool September 23, 2011 Dan Caplinger	Has Taseko Mines Become the Perfect Stock? Finding companies that have all the right stuff can produce winners.
The Motley Fool October 9, 2006 Brian Lawler	The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field.
The Motley Fool July 29, 2011 Sean Williams	Another Day, Another Loss For Cell Therapeutics Cell Therapeutics is giving shareholders that sinking feeling.
The Motley Fool August 4, 2011 Jim Royal	Things Remain On Track for the Market's Hottest Dividend Sector Mortgage REITs still look like a favorable opportunity.
The Motley Fool September 15, 2010 Brian Orelli	Cell Therapeutics Goes for Broke If Cell Therapeutics can't get new funding soon, long-term consequences may be the least of its worries; time on the clock looks to be running out.
The Motley Fool December 31, 2011 David Williamson	2011 Review: Cell Therapeutics After starting the year at a split-adjusted $2.22 a share, Cell Therapeutics stock lost almost 50% of its value by the end of December, closing at $1.16. How did we get here?
The Motley Fool January 18, 2011 Jim Royal	This Stock Is a 30-Bagger Look to the future, not the past for ideas on profitable stocks. Stocks analyzed in this article: Sirius XM, YRC Worldwide, Chimera, Allied Irish Banks, Altria, and SodaStream.
The Motley Fool July 20, 2010 Jordan DiPietro	Cell Therapeutics Finds a New Home The company signs a long-term agreement with an Italian manufacturer for a lymphoma treatment.
The Motley Fool February 3, 2010 Christopher Barker	One Step Closer to a Sure Thing Taseko Mines paves the path to prosperity. Taseko Mines scored extremely favorable terms on copper hedges announced this week for about half of the 2010 production from its flagship Gibraltar mine.
The Motley Fool May 4, 2011 Brian Orelli	Cell Therapeutics: Denied but Not Rejected Cell Therapeutics' ball may be headed for the end zone, but the FDA has an eight-foot free safety ready to bat it down.
The Motley Fool November 3, 2010 Christopher Barker	Taseko's Dead End to Prosperity Taseko suffers a major setback on the road to prosperity.
The Motley Fool October 19, 2010 Travis Hoium	Cell Therapeutics Shares Popped: What You Need to Know Cell Therapeutics shares jumped 11% today on news the company received a positive opinion for Pixuvri.
Investment Advisor December 2005 Greg B. Scott	Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns.
The Motley Fool July 27, 2010 Brian Orelli	Better Buy: Cell Therapeutics or Sequenom? Which one deserves your dollars more?
The Motley Fool November 3, 2011 Jim Royal	Bad News for Invesco and the Market's Hottest Dividend Sector? The issues at Invesco look company-specific.
The Motley Fool May 27, 2011 Brian Orelli	What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate.
The Motley Fool June 13, 2011 Christopher Barker	Taseko Stands Apart as a Bargain for Copper Taseko remains a treasure trove of deep value and growth potential.
The Motley Fool December 2, 2009 Christopher Barker	The Best Bargain in Miners Gets Better Taseko Mines sells a slice of copper to pan for gold.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool August 19, 2009 Christopher Barker	Copper's David and Goliaths Taseko Mines, the micro-cap copper miner with larger-than-life mineral reserves, earns admirers' attention in the second quarter.
The Motley Fool January 26, 2005 Stephen D. Simpson	The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities.
The Motley Fool January 4, 2012 Brian Orelli	Mark Your Calendars, Biotech Investors Cell Therapeutics' advisory panel meet ought to be entertaining.
The Motley Fool March 27, 2009 Christopher Barker	The Micro-Cap Miner With the Rock of Gibraltar Taseko Mines appears to be adapting effectively to these challenging conditions.
The Motley Fool August 5, 2011 Jim Royal	This High-Yield REIT Looks Gold-Plated Conditions still look favorable for this mortgage REIT.
The Motley Fool January 19, 2010 Christopher Barker	Taseko's Road Map to Prosperity The mining company takes another leap up.
The Motley Fool May 18, 2009 Brian Orelli	Is There Life After 600% Returns? Just because a drug company gets a massive increase in the stock price after a positive clinical trial or an FDA approval, that doesn't mean all the growth is completely factored into the stock price.
The Motley Fool August 2, 2004 Charly Travers	What's a Drug Worth? The value of small biotech companies is in their investigational drug programs.
The Motley Fool March 22, 2010 Christopher Barker	Ride the Shortest Road to Prosperity Taseko follows the path of least resistance. Among small-cap metal miners, few gems have shone as brightly as Taseko Mines
The Motley Fool July 15, 2010 Jason Moser	3 Stocks for a Diversified Portfolio Ideas large, small, and in between.
The Motley Fool July 30, 2010 Anand Chokkavelu	5 Stocks to Consider Before Buying Pfizer If you like Pfizer, you may like these five insurance and medical stocks better.
The Motley Fool November 12, 2010 Christopher Barker	Live Long and Prosper, Taseko While we don't yet know if Taseko Mines will succeed in resuscitating the company's recently flat-lined gold project in British Columbia, I have reason to believe that this intrepid copper miner will live long and prosper.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool May 20, 2011 Ilan Moscovitz	Rising Star Buys: Annaly Capital and Chimera Why we're buying.
The Motley Fool August 1, 2011 Dan Caplinger	Why It's Not Time to Panic Clear heads could make some serious money.
The Motley Fool August 9, 2010 Russ Krull	Annaly Capital Mangement: Strengths, Weaknesses, Opportunities, Threats Will Annaly's big yield hold up?
The Motley Fool July 12, 2011 Christopher Barker	7 Secrets to Profitable Gold Investing, Part 2 An overview of the key ingredients to successful gold investment.
The Motley Fool December 24, 2011 Ilan Moscovitz	2011: The Year Annaly Capital Kept Gushing Cash The year that was.
The Motley Fool December 22, 2003 Alyce Lomax	Losing Faith in Inspire Delay for its dry-eye treatment leaves investors uninspired.
The Motley Fool November 27, 2006 Brian Lawler	Pharmaxis Gets Good News From the FDA Fast-track designation gives this pharmaceutical stock a bump.
The Motley Fool March 3, 2009 Brian Orelli	A Tale of 2 Weeks It's been a busy two weeks at Genzyme as two nasty notes from the FDA follow two approvals.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool May 6, 2009 Christopher Barker	The Quarter We've Been Waiting For Yamana Gold is firing on all cylinders with impressive organic growth.